Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B

被引:12
|
作者
Liu Ning [1 ]
Zhao Li-jun [1 ]
Li Xiao-ping [1 ]
Wang Jian-liu [1 ]
Chai Guo-lin [2 ]
Wei Li-hui [1 ]
机构
[1] Peking Univ, Peoples Hosp, Dept Obstet & Gynecol, Beijing 100044, Peoples R China
[2] China Japan Friendship Hosp, Dept Hematol, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
histone deacetylase inhibitors; human cervical cancer; apoptosis; DNA-methyltransferase; 3B; Trichostatin A; DNA methyl transferase; SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION; THERAPY; DNMT1;
D O I
10.3760/cma.j.issn.0366-6999.2012.18.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Histone deacetylase (HDAC) inhibitors are a group of small chemical molecules that inhibit histone deacetylase. At cell level, HDAC inhibitors have multiple biological effects such as cell cycle arrest, apoptosis, cell differentiation and auotophagy. At molecular level, HDAC inhibitors cause histone and nonhistone acetylation and induce gene expression. HDAC inhibitors are widely used in cancer therapy because of its function of inducing apoptosis. However, the mechanisms of apoptosis effect are not fully understood. TSA is a classical HDAC inhibitor and widely used in epigenetic and anti-cancer research. In this study, we selected Trichostatin A (TSA) to investigate the mechanisms of HDAC inhibitors apoptotic effect on cancer cells. Methods Cervical cancer cell lines such as Hela, Caski and normal human keratinocyte line HaCaT were treated with various concentrations of TSA. Crystal violent assay and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were performed to determine cell number. PARP cleavage and FITC-AnexinV were performed to determine apoptosis. DNA-methyltransferase (DNMT)1, DNMT3A and DNMT3B were determined by regular PCR, qPCR and Western Blotting. Small interfering RNA (SiRNAi) was used to knock down DNMT3B. Results HDAC inhibitors only induce cervical cancer cell apoptosis. At 1 mu mol/L of TSA, 86% of Hela cell and 76% of Caski went apoptosis. For normal cells, HDAC inhibitors have no cytotoxic effect at therapeutic dosage, (90.0+/-8.4)% of normal cell survive after treated with 1 mu mol/L of TSA. We compared 1 mu mol/L group with untreated control with t-test. There was no significance between 1 mu mol/L group and untreated control for normal cell (P >0.05). HDAC inhibitors decreased DNMT3B in cancer cell but not in normal cell. Manually knock-down of DNMT3B induced Hela and Caski cell apoptosis. More than 99% of Hela and Caski cell went apoptosis after deprived of DNMT3B. Conclusions DNMT3B was essential to cervical cancer cell survival. Down-regulated DNMT3B by HDAC inhibitors may play an important role in the toxicity of HDAC inhibitors on cervical cancer cells. Chin Med J 2012;125(18):3273-3278
引用
收藏
页码:3273 / 3278
页数:6
相关论文
共 50 条
  • [31] Histone/Protein Deacetylase Inhibitors (HDACi) and DNA Methyltransferase Inhibitors (DNMTi) Enhance Human Treg Function Through Epigenetic Regulation of Foxp3
    Akimova, Tatiana
    Wang, Liqing
    Golovina, Tatiana N.
    Mikheeva, Tatiana V.
    Riley, James L.
    Hancock, Wayne W.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [32] The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study
    Erick de la Cruz-Hernández
    Enrique Pérez-Cárdenas
    Adriana Contreras-Paredes
    David Cantú
    Alejandro Mohar
    Marcela Lizano
    Alfonso Dueñas-González
    Virology Journal, 4
  • [33] The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study
    de la Cruz-Hernandez, Erick
    Perez-Cardenas, Enrique
    Contreras-Paredes, Adriana
    Cantu, David
    Mohar, Alejandro
    Lizano, Marcela
    Duenas-Gonzalez, Alfonso
    VIROLOGY JOURNAL, 2007, 4 (1)
  • [34] Structural insights into CpG-specific DNA methylation by human DNA methyltransferase 3B
    Lin, Chien-Chu
    Chen, Yi-Ping
    Yang, Wei-Zen
    Shen, James C. K.
    Yuan, Hanna S.
    NUCLEIC ACIDS RESEARCH, 2020, 48 (07) : 3949 - 3961
  • [35] Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors
    Ushio, Ryosuke
    Hiroi, Miki
    Matsumoto, Ari
    Mori, Kazumasa
    Yamamoto, Nobuharu
    Ohmori, Yoshihiro
    BIOMEDICINES, 2022, 10 (04)
  • [36] Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma
    Wang, Wuming
    Liu, Yuzhen
    Zhao, Long
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [37] Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A
    Caulfield, Thomas
    Medina-Franco, Jose L.
    JOURNAL OF STRUCTURAL BIOLOGY, 2011, 176 (02) : 185 - 191
  • [38] Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells
    Miyara, Makoto
    Chader, Driss
    Burlion, Aude
    Goldstein, Jeremie
    Sterlin, Delphine
    Norol, Francoise
    Trebeden-Negre, Helene
    Claer, Laetitia
    Sakaguchi, Shimon
    Marodon, Gilles
    Amoura, Zahir
    Gorochov, Guy
    ONCOTARGET, 2017, 8 (62): : 104733 - 104744
  • [39] Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
    Yanrong Su
    Nathan R. Hopfinger
    Theresa D. Nguyen
    Thomas J. Pogash
    Julia Santucci-Pereira
    Jose Russo
    Journal of Experimental & Clinical Cancer Research, 37
  • [40] Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
    Su, Yanrong
    Hopfinger, Nathan R.
    Nguyen, Theresa D.
    Pogash, Thomas J.
    Santucci-Pereira, Julia
    Russo, Jose
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37